Dianthus Therapeutics Inc
DNTH39.020USD
+0.140+0.36%
交易中 （美东）报价延迟15分钟
1.26B总市值
亏损市盈率 TTM
关于 Dianthus Therapeutics Inc 公司
Dianthus Therapeutics, Inc. 是一家临床阶段的生物技术公司，致力于推进抗体补体疗法，以治疗严重的自身免疫性疾病。该公司致力于设计和提供具有更高选择性和效力的单克隆抗体。该公司已启动 DNTH103（一种潜在的活性 C1s 抑制剂）在全身性重症肌无力中的 2 期试验，并计划启动其他神经肌肉适应症的 2 期试验，包括多灶性运动神经病和慢性炎症性脱髓鞘性多发性神经病。其候选产品 DNTH103 是一种临床阶段的高效、高选择性和完全人源化的单克隆免疫球蛋白 G4，具有皮摩尔结合亲和力，旨在选择性地仅与 C1s 补体蛋白的活性形式结合。DNTH103 采用 YTE 半衰期延长技术设计，Fc 结构域中有特定的三个氨基酸变化，并具有药代动力学 (PK) 特征。
公司简介
公司代码DNTH
公司名称Dianthus Therapeutics Inc
上市日期Jun 21, 2018
CEOMr. Marino Garcia
员工数量78
证券类型Ordinary Share
年结日Jun 21
公司地址7 Times Square
城市NEW YORK
上市交易所NASDAQ Capital Market Consolidated
国家United States of America
邮编10036
电话19299994055
网址https://dianthustx.com/
公司代码DNTH
上市日期Jun 21, 2018
CEOMr. Marino Garcia
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Simrat Randhawa, M.D.
Dr. Simrat Randhawa, M.D.
Chief Medical Officer
Chief Medical Officer
4.00K
--
Dr. Simon Read, Ph.D.
Dr. Simon Read, Ph.D.
Independent Director
Independent Director
--
--
Ms. Anne McGeorge
Ms. Anne McGeorge
Independent Director
Independent Director
--
--
Mr. Sujay Kango
Mr. Sujay Kango
Independent Director
Independent Director
--
--
Mr. Marino Garcia
Mr. Marino Garcia
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Paula Soteropoulos
Ms. Paula Soteropoulos
Independent Director
Independent Director
--
--
Dr. Jonathan Violin, Ph.D.
Dr. Jonathan Violin, Ph.D.
Independent Director
Independent Director
--
--
Mr. John C. King
Mr. John C. King
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Ryan Savitz
Mr. Ryan Savitz
Chief Financial Officer, Chief Business Officer Treasurer
Chief Financial Officer, Chief Business Officer Treasurer
--
--
Mr. Adam M. Veness, Esq., J.D.
Mr. Adam M. Veness, Esq., J.D.
Senior Vice President, General Counsel, Company Secretary
Senior Vice President, General Counsel, Company Secretary
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Simrat Randhawa, M.D.
Dr. Simrat Randhawa, M.D.
Chief Medical Officer
Chief Medical Officer
4.00K
--
Dr. Simon Read, Ph.D.
Dr. Simon Read, Ph.D.
Independent Director
Independent Director
--
--
Ms. Anne McGeorge
Ms. Anne McGeorge
Independent Director
Independent Director
--
--
Mr. Sujay Kango
Mr. Sujay Kango
Independent Director
Independent Director
--
--
Mr. Marino Garcia
Mr. Marino Garcia
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Paula Soteropoulos
Ms. Paula Soteropoulos
Independent Director
Independent Director
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 8月19日 周二
更新时间: 8月19日 周二
持股股东
股东类型
持股股东
持股股东
占比
Fidelity Management & Research Company LLC
11.18%
Fairmount Funds Management LLC
8.31%
Vestal Point Capital, LP
8.04%
RA Capital Management, LP
7.20%
Bain Capital Life Sciences Investors, LLC
6.24%
其他
59.04%
持股股东
持股股东
占比
Fidelity Management & Research Company LLC
11.18%
Fairmount Funds Management LLC
8.31%
Vestal Point Capital, LP
8.04%
RA Capital Management, LP
7.20%
Bain Capital Life Sciences Investors, LLC
6.24%
其他
59.04%
股东类型
持股股东
占比
Hedge Fund
36.36%
Investment Advisor
31.37%
Investment Advisor/Hedge Fund
16.59%
Venture Capital
14.66%
Corporation
6.35%
Research Firm
1.83%
Pension Fund
0.09%
Bank and Trust
0.06%
Family Office
0.04%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
225
41.02M
127.55%
+261.80K
2025Q1
235
40.76M
126.74%
+1.19M
2024Q4
225
37.90M
128.07%
+500.72K
2024Q3
228
34.16M
116.90%
-861.66K
2024Q2
212
32.37M
110.91%
+1.86M
2024Q1
216
28.72M
99.95%
+5.46M
2023Q4
215
12.76M
88.36%
-987.59K
2023Q3
226
11.26M
78.30%
+6.74M
2023Q2
233
1.90M
50.21%
-2.51M
2023Q1
239
1.94M
51.29%
-1.60M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Fidelity Management & Research Company LLC
4.37M
13.6%
+43.33K
+1.00%
Mar 31, 2025
Fairmount Funds Management LLC
2.70M
8.4%
--
--
Mar 31, 2025
Vestal Point Capital, LP
1.70M
5.29%
+625.07K
+58.15%
Mar 31, 2025
RA Capital Management, LP
2.87M
8.91%
+1.00M
+53.60%
Mar 31, 2025
Bain Capital Life Sciences Investors, LLC
2.69M
8.36%
--
--
Mar 31, 2025
Octagon Capital Advisors LP
2.34M
7.28%
+231.50K
+10.97%
Mar 31, 2025
Deep Track Capital LP
2.36M
7.33%
+2.36M
--
Mar 31, 2025
Avidity Partners Management LP
1.72M
5.35%
-1.15M
-40.10%
Mar 31, 2025
TCG Crossover Management, LLC
1.50M
4.67%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
1.11M
3.45%
-163.43K
-12.85%
Mar 31, 2025
查看更多
持股ETF
更新时间: 9月2日 周二
更新时间: 9月2日 周二
机构名称
占比
Virtus LifeSci Biotech Clinical Trials ETF
1.27%
iShares Neuroscience and Healthcare ETF
1.13%
Harbor Health Care ETF
0.55%
ALPS Medical Breakthroughs ETF
0.4%
SPDR S&P Biotech ETF
0.15%
Direxion Daily S&P Biotech Bull 3X Shares
0.1%
iShares Micro-Cap ETF
0.09%
Avantis US Small Cap Equity ETF
0.07%
iShares Russell 2000 Value ETF
0.03%
ProShares UltraPro Russell2000
0.02%
查看更多
Virtus LifeSci Biotech Clinical Trials ETF
占比1.27%
iShares Neuroscience and Healthcare ETF
占比1.13%
Harbor Health Care ETF
占比0.55%
ALPS Medical Breakthroughs ETF
占比0.4%
SPDR S&P Biotech ETF
占比0.15%
Direxion Daily S&P Biotech Bull 3X Shares
占比0.1%
iShares Micro-Cap ETF
占比0.09%
Avantis US Small Cap Equity ETF
占比0.07%
iShares Russell 2000 Value ETF
占比0.03%
ProShares UltraPro Russell2000
占比0.02%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
Sep 11, 2023
Merger
16→1
Sep 11, 2023
Merger
16→1
Sep 11, 2023
Merger
16→1
Sep 11, 2023
Merger
16→1
公告日期
类型
比率
Sep 11, 2023
Merger
16→1
Sep 11, 2023
Merger
16→1
Sep 11, 2023
Merger
16→1
Sep 11, 2023
Merger
16→1
